Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCTNYSEAMERICAN:BPMXCVE:HEMNASDAQ:SBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsBPMXBiopharmx$0.00$0.25▼$6.30$111.86MN/A2.15 million shs336,508 shsHEMHemostemixC$0.14C$0.11C$0.04▼C$0.43C$20.40M0.2413,602 shs81,445 shsSBTXSilverback Therapeutics$16.52-1.4%$14.79$2.80▼$8.97$595.68M0.6337,931 shs881,491 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%BPMXBiopharmx0.00%0.00%0.00%0.00%0.00%HEMHemostemix0.00%+3.70%+21.74%+40.00%+180.00%SBTXSilverback Therapeutics0.00%-9.23%+22.92%+29.06%+81.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideBPMXBiopharmx 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/ABPMXBiopharmxN/AN/A0.00N/AN/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68BPMXBiopharmxN/AN/AN/AHEMHemostemix-55.070.040.48SBTXSilverback TherapeuticsN/A67.8767.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/ABPMXBiopharmxN/AHEMHemostemixN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/ABPMXBiopharmxN/AHEMHemostemix10.43%SBTXSilverback Therapeutics34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableBPMXBiopharmx1718.28 millionN/ANot OptionableHEMHemostemixN/A145.73 millionN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableBPMX, ANR, SBTX, BCT, and HEM HeadlinesRecent News About These CompaniesSilverback Therapeutics (NASDAQ:SBTX) Trading Up 4.9% - Here's WhyJune 25, 2025 | marketbeat.comMeet the Silverback, the Leader of the TroopOctober 17, 2024 | pbs.orgP10 Fun Facts About Mountain GorillasSeptember 18, 2024 | nationalgeographic.comNCapstanTx secures $165 million to deliver precise in vivo cell engineeringJuly 28, 2024 | pharmaphorum.comPARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comWild IslesMarch 12, 2023 | wwf.org.ukWA look back at RNA Therapeutics – day oneFebruary 23, 2023 | pharmaphorum.comPSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comFDA accepts ARS Pharma’s NDA for NeffyOctober 24, 2022 | thepharmaletter.comTSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 23, 2022 | kentuckytoday.comKSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 19, 2022 | aaii.comASHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNOctober 12, 2022 | bakersfield.comBINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSeptember 6, 2022 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPMX, ANR, SBTX, BCT, and HEM Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Biopharmx NYSEAMERICAN:BPMXBioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.Hemostemix CVE:HEMC$0.14 0.00 (0.00%) As of 07/4/2025 10:34 AM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Silverback Therapeutics NASDAQ:SBTX$16.52 -0.23 (-1.37%) As of 07/3/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
